Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR Followed by Zevalin for Non-Follicular Indolent Lymphomas
NCT00354822Phase 2Terminated
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Aug 2005
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in small lymphocytic lymphoma (SLL), Lymphoplasmacytic Lymphoma (LPL), marginal zone lymphoma (MZL), sponsored by Papa Giovanni XXIII Hospital. Started Aug 2005; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
small lymphocytic lymphoma (SLL)Lymphoplasmacytic Lymphoma (LPL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00354822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354822.